UBS AM
RAPP

UBS AM’s Rapport Therapeutics RAPP Stock Holding History

UBS AM’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.8M Sell
644,082
-274,784
-30% -$10.1M ﹤0.01% 827
2026
Q1 		$28.8M Sell
918,866
-33,505
-4% -$942K 0.01% 762
2025
Q4 		$28.9M Buy
952,371
+60,113
+7% +$1.66M 0.01% 737
2025
Q3 		$26.5M Buy
892,258
+648,378
+266% +$11.6M 0.01% 739
2025
Q2 		$2.77M Buy
243,880
+40,638
+20% +$431K ﹤0.01% 1994
2025
Q1 		$2.04M Buy
+203,242
New +$2.64M ﹤0.01% 1982

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

UBS AM's RAPP Position: Q2 2026 in Review

UBS AM reduced its Rapport Therapeutics (RAPP) stake by 30% in Q2 2026, selling an estimated $10.1M and leaving 644,082 shares worth $26.8M. The position accounts for ﹤0.01% of the portfolio, ranked #827.

UBS AM first reported a position in RAPP in Q1 2025 and has held it in 6 quarters since. The position peaked at $28.9M in Q4 2025. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • UBS AM held 644,082 shares of Rapport Therapeutics worth $26.8M as of Q2 2026.
  • UBS AM sold 274,784 Rapport Therapeutics shares in Q2 2026, an estimated $10.1M.
  • Rapport Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #827 holding.
  • UBS AM first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • UBS AM's Rapport Therapeutics position peaked at $28.9M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.